When it comes to the diabetes tech market, the Insulet (Nasdaq:PODD) Omnipod 5 automated insulin delivery system is nothing new.
Omnipod 5 first received FDA clearance for individuals aged six years old and up with type 1 diabetes in January 2022. At that point, it became the world’s first available tubeless, wearable, automated insulin delivery system.
In the more than three years since, the company has continued to expand the technology in a multitude of ways. More people around the world can use it, as can more children and more people with diabetes who couldn’t use automated insulin delivery before. Last year’s American Diabetes Association Scientific Sessions was the launchpad for the company’s bid to bring automated insulin delivery to the type 2 diabetes population, with the publication of SECURE-T2D data highlighting the system’s capabilities.
Omnipod 5 became the first and only such system cleared for type 1 and type 2 diabetes last August. The company has only continued to build from there. That includes a new partnership with none other than Marvel, creating a comic book hero with diabetes.
At this year’s ADA Scientific Sessions in Chicago, Insulet SVP Chief Medical Officer, Dr. Trang Ly, spoke to Drug Delivery Business News about the latest developments at Insulet as it looks to bring the insulin patch pump to even more users.
“We’re really happy with our product adoption,” Ly said. “You can see by our growth. It’s a very simple and easy to use product and it reaches a lot more patients than other products on the market.”
Get the full story at our sister site, Drug Delivery Business News.
